During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal cell carcinoma, highlighting management of anemia and hypoxia.
Sequencing for Metastatic Clear Cell Renal Cell Carcinoma After Prior Therapy
Experts discuss second-line treatment strategies for clear cell renal cell carcinoma, focusing on efficacy, tolerability, and the role of tivozanib.
During a live event, Nizar M. Tannir, MD and participants discussed their takeaways from trial data on recurrent RCC treatment and their personal experiences.
During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when choosing frontline regimens for advanced renal cell carcinoma.
During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic renal cell carcinoma.
During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient with post-immunotherapy progression.
During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal cell carcinoma.
During a live event, Chandler H. Park, MD, and event participants looked at quality of life, tolerability, and rechallenging in second-line RCC therapy.
During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after immune checkpoint inhibitors.
During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity.
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.
During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants depending on their own practice and trial data for a patient with clear cell renal cell carcinoma.
During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed regimens for recurrent metastatic clear cell renal cell carcinoma including lenvatinib plus everolimus, belzutifan, and investigational cell therapy and bispecific agents in the second article of a 2-part series.
During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed long-term outcomes of the TIVO-3 trial in patients with metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, and participants explored the third-line treatment options for a patient with advanced renal cell carcinoma. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the case of an older patient with metastatic renal cell carcinoma who had recurrent disease after receiving axitinib and pembrolizumb, then single-agent cabozantinib. This is the first of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, asked participants about what sequence of therapies they would use in the first, second, and third lines for a patient with metastatic clear cell renal cell carcinoma. This is the first of 2 articles based on this event.
In the second article of a 2-part series, Sumanta K. Pal, MD, leads a discussion on what therapies physicians consider in the later-line settings for treatment of patients with advanced renal cell carcinoma.
In the first article of a 2-part series, Sumanta K. Pal, MD, leads a discussion on considerations for the treatment of patients with relapsed/refractory renal cell carcinoma in the third-line setting.
In the second article of a 2-part series, Hans Hammers, MD, PhD, leads a discussion on the adverse events seen with the use of tyrosine kinase inhibitors in the treatment of patients with renal cell carcinoma.
In part 1 of a 2-part series, Hans Hammers, MD, PhD, discusses the current landscape for treating patients with advanced renal cell carcinoma who have had 1 or 2 prior therapies and how tivozanib fits into current treatment practices.
During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed with participants their experiences using tivozanib and lenvatinib/everolimus in patients who have received at least 2 prior lines of therapy for advanced renal cell carcinoma. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed possible therapy options for a patient with metastatic renal cell carcinoma whose disease progressed on frontline therapy.
With updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.
Chung-Han Lee, MD, PhD, discusses the most important factors in treatment selection for later-line therapy in renal cell carcinoma.
Benjamin Garmezy, MD, discusses the choice of third-line therapies in patients with advanced renal cell carcinoma.
During a Targeted Oncology case-based roundtable event, Saby George, MD, and participants discussed the role of tivozanib and other later-line options in patients with advanced renal cell carcinoma.
During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.